{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:45:59Z","timestamp":1791931559862,"version":"4.3.4"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QH113"],"award-info":[{"award-number":["ZR2023QH113"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04964-z","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T05:03:14Z","timestamp":1791781394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody\u2013drug conjugates in lung cancer: clinical development, therapeutic advances, and emerging challenges"],"prefix":"10.1007","volume":"96","author":[{"given":"Yilin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoran","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"6","key":"4964_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrc2394","volume":"8","author":"K Strebhardt","year":"2008","unstructured":"Strebhardt K, Ullrich A (2008) Paul Ehrlich\u2019s magic bullet concept: 100 years of progress. Nat Rev Cancer 8(6):473\u2013480. https:\/\/doi.org\/10.1038\/nrc2394","journal-title":"Nat Rev Cancer"},{"key":"4964_CR2","doi-asserted-by":"publisher","first-page":"108106","DOI":"10.1016\/j.pharmthera.2021.108106","volume":"236","author":"C Ceci","year":"2022","unstructured":"Ceci C, Lacal PM, Graziani G (2022) Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential. Pharmacol Ther 236:108106. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.108106","journal-title":"Pharmacol Ther"},{"key":"4964_CR3","doi-asserted-by":"publisher","first-page":"e389968","DOI":"10.1200\/edbk_389968","volume":"43","author":"S Rosner","year":"2023","unstructured":"Rosner S, Valdivia A, Hoe HJ, Murray JC, Levy B, Felip E et al (2023) Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress. Am Soc Clin Oncol Educ Book 43:e389968. https:\/\/doi.org\/10.1200\/edbk_389968","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"31","key":"4964_CR4","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1200\/jco.23.01361","volume":"41","author":"K Goto","year":"2023","unstructured":"Goto K, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D et al (2023) Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. J Clin Oncol 41(31):4852\u20134863. https:\/\/doi.org\/10.1200\/jco.23.01361","journal-title":"J Clin Oncol"},{"issue":"3","key":"4964_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazi\u00e8res J et al (2022) Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med 386(3):241\u2013251. https:\/\/doi.org\/10.1056\/NEJMoa2112431","journal-title":"N Engl J Med"},{"issue":"21","key":"4964_CR6","doi-asserted-by":"publisher","first-page":"e70090","DOI":"10.1002\/cncr.70090","volume":"131","author":"L Lawrence","year":"2025","unstructured":"Lawrence L (2025) FDA approves second-line TROP2-directed antibody-drug conjugate Dato-DXd for EGFR-mutated NSCLC. Cancer 131(21):e70090. https:\/\/doi.org\/10.1002\/cncr.70090","journal-title":"Cancer"},{"issue":"4","key":"4964_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.5582\/ddt.2025.01058","volume":"19","author":"C Zhao","year":"2025","unstructured":"Zhao C, Lu D, Gao J (2025) Telisotuzumab vedotin: The first-in-class c-Met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC). Drug Discov Ther 19(4):275\u2013276. https:\/\/doi.org\/10.5582\/ddt.2025.01058","journal-title":"Drug Discov Ther"},{"issue":"1","key":"4964_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41698-022-00338-9","volume":"7","author":"N Coleman","year":"2023","unstructured":"Coleman N, Yap TA, Heymach JV, Meric-Bernstam F, Le X (2023) Antibody-drug conjugates in lung cancer: dawn of a new era? NPJ Precis Oncol 7(1):5. https:\/\/doi.org\/10.1038\/s41698-022-00338-9","journal-title":"NPJ Precis Oncol"},{"issue":"4","key":"4964_CR9","doi-asserted-by":"publisher","first-page":"e70090","DOI":"10.3322\/caac.70090","volume":"76","author":"H Sung","year":"2026","unstructured":"Sung H, Filho AM, Laversanne M, Ferlay J, Siegel RL, Soerjomataram I et al (2026) Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin 76(4):e70090. https:\/\/doi.org\/10.3322\/caac.70090","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"4964_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S (2021) Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol 18(6):327\u2013344. https:\/\/doi.org\/10.1038\/s41571-021-00470-8","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"4964_CR11","doi-asserted-by":"publisher","first-page":"e10677","DOI":"10.1002\/btm2.10677","volume":"9","author":"E Udofa","year":"2024","unstructured":"Udofa E, Sankholkar D, Mitragotri S, Zhao Z (2024) Antibody drug conjugates in the clinic. Bioeng Transl Med 9(6):e10677. https:\/\/doi.org\/10.1002\/btm2.10677","journal-title":"Bioeng Transl Med"},{"issue":"1","key":"4964_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","volume":"13","author":"J Yu","year":"2020","unstructured":"Yu J, Song Y, Tian W (2020) How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol 13(1):45. https:\/\/doi.org\/10.1186\/s13045-020-00876-4","journal-title":"J Hematol Oncol"},{"key":"4964_CR13","doi-asserted-by":"crossref","unstructured":"Kim S, Jo M, Kyung M, Ko WH, Lee W, Chang K et al (2026) A stealth-body Fc engineering platform enables complete efiector silencing in antibody and ADC","DOI":"10.1186\/s13036-026-00735-9"},{"key":"4964_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","volume":"200","author":"PK Mahalingaiah","year":"2019","unstructured":"Mahalingaiah PK, Ciurlionis R, Durbin KR, Yeager RL, Philip BK, Bawa B et al (2019) Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther 200:110\u2013125. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.04.008","journal-title":"Pharmacol Ther"},{"issue":"22","key":"4964_CR15","doi-asserted-by":"publisher","first-page":"9182","DOI":"10.1039\/d2cs00446a","volume":"51","author":"N Ashman","year":"2022","unstructured":"Ashman N, Bargh JD, Spring DR (2022) Non-internalising antibody-drug conjugates. Chem Soc Rev 51(22):9182\u20139202. https:\/\/doi.org\/10.1039\/d2cs00446a","journal-title":"Chem Soc Rev"},{"issue":"1","key":"4964_CR16","doi-asserted-by":"publisher","first-page":"2645769","DOI":"10.1080\/10717544.2026.2645769","volume":"33","author":"C Feng","year":"2026","unstructured":"Feng C, Lou R, Chen S, Lin F, Ge J, Zhang Y et al (2026) Extracellular payload release from non-internalizing antibody-drug conjugates: mechanisms and linker technologies. Drug Deliv 33(1):2645769. https:\/\/doi.org\/10.1080\/10717544.2026.2645769","journal-title":"Drug Deliv"},{"issue":"7","key":"4964_CR17","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","volume":"24","author":"F Giugliano","year":"2022","unstructured":"Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G (2022) Bystander effect of antibody-drug conjugates: fact or fiction? Curr Oncol Rep 24(7):809\u2013817. https:\/\/doi.org\/10.1007\/s11912-022-01266-4","journal-title":"Curr Oncol Rep"},{"issue":"16","key":"4964_CR18","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/c8cs00676h","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh JD, Isidro-Llobet A, Parker JS, Spring DR (2019) Cleavable linkers in antibody-drug conjugates. Chem Soc Rev 48(16):4361\u20134374. https:\/\/doi.org\/10.1039\/c8cs00676h","journal-title":"Chem Soc Rev"},{"issue":"12","key":"4964_CR19","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","volume":"11","author":"Z Su","year":"2021","unstructured":"Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S et al (2021) Antibody-drug conjugates: Recent advances in linker chemistry. Acta Pharm Sin B 11(12):3889\u20133907. https:\/\/doi.org\/10.1016\/j.apsb.2021.03.042","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"4964_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/abt\/tbaf010","volume":"8","author":"Q Fan","year":"2025","unstructured":"Fan Q, Chen H, Wei G, Wei D, Wang Z, Zhang L et al (2025) A review of conjugation technologies for antibody drug conjugates. Antib Ther 8(2):157\u2013170. https:\/\/doi.org\/10.1093\/abt\/tbaf010","journal-title":"Antib Ther"},{"issue":"1","key":"4964_CR21","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1039\/D3CS00715D","volume":"53","author":"P Chauhan","year":"2024","unstructured":"Chauhan P, V R, Kumar M, Molla R, Mishra SD, Basa S et al (2024) Chemical technology principles for selective bioconjugation of proteins and antibodies. Chem Soc Rev 53(1):380\u2013449","journal-title":"Chem Soc Rev"},{"issue":"5","key":"4964_CR22","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1158\/1535-7163.Mct-16-0038","volume":"15","author":"PJ Burke","year":"2016","unstructured":"Burke PJ, Hamilton JZ, Pires TA, Setter JR, Hunter JH, Cochran JH et al (2016) Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates. Mol Cancer Ther 15(5):938\u2013945. https:\/\/doi.org\/10.1158\/1535-7163.Mct-16-0038","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"4964_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40259-025-00752-y","volume":"40","author":"N Kim","year":"2026","unstructured":"Kim N, Kwon I (2026) Conditionally Activatable Antibody Platforms: Mechanisms, Modalities, and Clinical Translation Potential. BioDrugs 40(1):79\u2013108. https:\/\/doi.org\/10.1007\/s40259-025-00752-y","journal-title":"BioDrugs"},{"issue":"1","key":"4964_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","volume":"7","author":"S Jin","year":"2022","unstructured":"Jin S, Sun Y, Liang X, Gu X, Ning J, Xu Y et al (2022) Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther 7(1):39. https:\/\/doi.org\/10.1038\/s41392-021-00868-x","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4964_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","volume":"16","author":"L Conilh","year":"2023","unstructured":"Conilh L, Sadilkova L, Viricel W, Dumontet C (2023) Payload diversification: a key step in the development of antibody-drug conjugates. J Hematol Oncol 16(1):3. https:\/\/doi.org\/10.1186\/s13045-022-01397-y","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4964_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/1078-0432.Ccr-13-0541","volume":"20","author":"I Krop","year":"2014","unstructured":"Krop I, Winer EP (2014) Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Clin Cancer Res 20(1):15\u201320. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-0541","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4964_CR27","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1158\/1078-0432.Ccr-09-2069","volume":"16","author":"NM Okeley","year":"2010","unstructured":"Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL et al (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 16(3):888\u2013897. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-09-2069","journal-title":"Clin Cancer Res"},{"key":"4964_CR28","doi-asserted-by":"publisher","first-page":"118737","DOI":"10.1016\/j.bmc.2026.118737","volume":"141","author":"X Yu","year":"2026","unstructured":"Yu X, Yu D, Wang Y, Jiang B, Chen H (2026) Recent advances in Camptothecin-derived antibody-drug conjugates. Bioorg Med Chem 141:118737. https:\/\/doi.org\/10.1016\/j.bmc.2026.118737","journal-title":"Bioorg Med Chem"},{"issue":"16","key":"4964_CR29","doi-asserted-by":"publisher","first-page":"169841","DOI":"10.1016\/j.jmb.2026.169841","volume":"438","author":"Y Pommier","year":"2026","unstructured":"Pommier Y (2026) Molecular Determinants of Response and Rational Drug Combinations for Antibody-Drug Conjugates (ADCs) with Topoisomerase I (TOP1) Inhibitor Payloads. J Mol Biol 438(16):169841. https:\/\/doi.org\/10.1016\/j.jmb.2026.169841","journal-title":"J Mol Biol"},{"issue":"8","key":"4964_CR30","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/d41573-025-00121-y","volume":"24","author":"A Mullard","year":"2025","unstructured":"Mullard A (2025) Dual-payload ADCs move into first oncology clinical trials. Nat Rev Drug Discov 24(8):573\u2013576. https:\/\/doi.org\/10.1038\/d41573-025-00121-y","journal-title":"Nat Rev Drug Discov"},{"key":"4964_CR31","doi-asserted-by":"publisher","first-page":"116378","DOI":"10.1016\/j.bcp.2024.116378","volume":"226","author":"C Zhao","year":"2024","unstructured":"Zhao C, Zhang R, Yang H, Gao Y, Zou Y, Zhang X (2024) Antibody-drug conjugates for non-small cell lung cancer: Advantages and challenges in clinical translation. Biochem Pharmacol 226:116378. https:\/\/doi.org\/10.1016\/j.bcp.2024.116378","journal-title":"Biochem Pharmacol"},{"issue":"10454","key":"4964_CR32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/s0140-6736(24)01029-8","volume":"404","author":"ML Meyer","year":"2024","unstructured":"Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, J\u00e4nne PA, Peters S et al (2024) New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet 404(10454):803\u2013822. https:\/\/doi.org\/10.1016\/s0140-6736(24)01029-8","journal-title":"Lancet"},{"issue":"7","key":"4964_CR33","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/s41417-024-00778-4","volume":"31","author":"Y Tang","year":"2024","unstructured":"Tang Y, Pu X, Yuan X, Pang Z, Li F, Wang X (2024) Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential. Cancer Gene Ther 31(7):961\u2013969. https:\/\/doi.org\/10.1038\/s41417-024-00778-4","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"4964_CR34","doi-asserted-by":"publisher","first-page":"100395","DOI":"10.1016\/j.esmoop.2022.100395","volume":"7","author":"S Ren","year":"2022","unstructured":"Ren S, Wang J, Ying J, Mitsudomi T, Lee DH, Wang Z et al (2022) Consensus for HER2 alterations testing in non-small-cell lung cancer. ESMO Open 7(1):100395. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100395","journal-title":"ESMO Open"},{"key":"4964_CR35","doi-asserted-by":"publisher","first-page":"102520","DOI":"10.1016\/j.ctrv.2023.102520","volume":"114","author":"Y Yu","year":"2023","unstructured":"Yu Y, Yang Y, Li H, Fan Y (2023) Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges. Cancer Treat Rev 114:102520. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102520","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"4964_CR36","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1158\/2159-8290.Cd-20-0215","volume":"10","author":"BT Li","year":"2020","unstructured":"Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y et al (2020) HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. Cancer Discov 10(5):674\u2013687. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-0215","journal-title":"Cancer Discov"},{"issue":"7Supplement","key":"4964_CR37","doi-asserted-by":"publisher","first-page":"CT248","DOI":"10.1158\/1538-7445.AM2024-CT248","volume":"84","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Wu L, Fang Y, Fan Y, Li X, Zhang M et al (2024) Abstract CT248: trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the phase 2 DESTINY-Lung05 (DL-05) trial. Cancer Res 84(7Supplement):CT248\u2013CT","journal-title":"Cancer Res"},{"key":"4964_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.07.129","author":"PA J\u00e4nne","year":"2025","unstructured":"J\u00e4nne PA, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D et al (2025) Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC. J Thorac Oncol. https:\/\/doi.org\/10.1016\/j.jtho.2025.07.129","journal-title":"J Thorac Oncol"},{"issue":"4","key":"4964_CR39","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/s1470-2045(24)00064-0","volume":"25","author":"EF Smit","year":"2024","unstructured":"Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodr\u00edguez L et al (2024) Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncol 25(4):439\u2013454. https:\/\/doi.org\/10.1016\/s1470-2045(24)00064-0","journal-title":"Lancet Oncol"},{"key":"4964_CR40","doi-asserted-by":"publisher","unstructured":"Planchard D, Kim HR, Suksombooncharoen T, Li R, Cortinovis D, Han JY et al (2025) Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial. J Thorac Oncol 103541. https:\/\/doi.org\/10.1016\/j.jtho.2025.12.080","DOI":"10.1016\/j.jtho.2025.12.080"},{"key":"4964_CR41","doi-asserted-by":"crossref","unstructured":"Li BT, Ahn M-J, Goto K, Mazieres J, Padda SK, William WN et al (2022) Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non\u2013small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04). American Society of Clinical Oncology","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9137"},{"issue":"29","key":"4964_CR42","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1200\/jco.23.02044","volume":"42","author":"H Yao","year":"2024","unstructured":"Yao H, Yan M, Tong Z, Wu X, Ryu MH, Park JJ et al (2024) Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial. J Clin Oncol 42(29):3453\u20133465. https:\/\/doi.org\/10.1200\/jco.23.02044","journal-title":"J Clin Oncol"},{"issue":"4","key":"4964_CR43","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/s1470-2045(25)00012-9","volume":"26","author":"Z Li","year":"2025","unstructured":"Li Z, Wang Y, Sun Y, Wang L, Li X, Sun L et al (2025) Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study. Lancet Oncol 26(4):437\u2013446. https:\/\/doi.org\/10.1016\/s1470-2045(25)00012-9","journal-title":"Lancet Oncol"},{"issue":"1","key":"4964_CR44","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41392-024-01897-y","volume":"9","author":"Z Li","year":"2024","unstructured":"Li Z, Song Z, Hong W, Yang N, Wang Y, Jian H et al (2024) SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1\/2 study. Signal Transduct Target Ther 9(1):182. https:\/\/doi.org\/10.1038\/s41392-024-01897-y","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"4964_CR45","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/1078-0432.Ccr-23-2566","volume":"30","author":"A Bessede","year":"2024","unstructured":"Bessede A, Peyraud F, Besse B, Cousin S, Cabart M, Chomy F et al (2024) TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res 30(4):779\u2013785. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-2566","journal-title":"Clin Cancer Res"},{"issue":"24","key":"4964_CR46","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1200\/jco.24.01043","volume":"42","author":"M P\u00e9rol","year":"2024","unstructured":"P\u00e9rol M (2024) TROP2-Directed Antibody-Drug Conjugates in Advanced Non-Small Cell Lung Cancer: A Fading Hope? J Clin Oncol 42(24):2839\u20132842. https:\/\/doi.org\/10.1200\/jco.24.01043","journal-title":"J Clin Oncol"},{"issue":"12","key":"4964_CR47","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.Mct-21-0206","volume":"20","author":"D Okajima","year":"2021","unstructured":"Okajima D, Yasuda S, Maejima T, Karibe T, Sakurai K, Aida T et al (2021) Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Mol Cancer Ther 20(12):2329\u20132340. https:\/\/doi.org\/10.1158\/1535-7163.Mct-21-0206","journal-title":"Mol Cancer Ther"},{"issue":"29","key":"4964_CR48","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1200\/jco.23.00059","volume":"41","author":"T Shimizu","year":"2023","unstructured":"Shimizu T, Sands J, Yoh K, Spira A, Garon EB, Kitazono S et al (2023) First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01. J Clin Oncol 41(29):4678\u20134687. https:\/\/doi.org\/10.1200\/jco.23.00059","journal-title":"J Clin Oncol"},{"issue":"10","key":"4964_CR49","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1200\/JCO-24-01349","volume":"43","author":"J Sands","year":"2025","unstructured":"Sands J, Ahn M-J, Lisberg A, Cho BC, Blumenschein G Jr, Shum E et al (2025) Datopotamab deruxtecan in advanced or metastatic non\u2013small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study. J Clin Oncol 43(10):1254\u20131265","journal-title":"J Clin Oncol"},{"issue":"5","key":"4964_CR50","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1177\/10600280251393259","volume":"60","author":"R Lucky","year":"2026","unstructured":"Lucky R, Thornburg L, Halford Z (2026) Targeting TROP2 Across Solid Tumors: The Clinical Profile and Role of Datopotamab Deruxtecan. Ann Pharmacother 60(5):486\u2013499","journal-title":"Ann Pharmacother"},{"issue":"8","key":"4964_CR51","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR et al (2019) Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med 380(8):741\u2013751. https:\/\/doi.org\/10.1056\/NEJMoa1814213","journal-title":"N Engl J Med"},{"issue":"24","key":"4964_CR52","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1200\/jco.24.00733","volume":"42","author":"LG Paz-Ares","year":"2024","unstructured":"Paz-Ares LG, Juan-Vidal O, Mountzios GS, Felip E, Reinmuth N, de Marinis F et al (2024) Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol 42(24):2860\u20132872. https:\/\/doi.org\/10.1200\/jco.24.00733","journal-title":"J Clin Oncol"},{"key":"4964_CR53","doi-asserted-by":"publisher","first-page":"951589","DOI":"10.3389\/fonc.2022.951589","volume":"12","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Yuan X, Tian Q, Huang X, Chen Y, Pu Y et al (2022) Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132. Front Oncol 12:951589. https:\/\/doi.org\/10.3389\/fonc.2022.951589","journal-title":"Front Oncol"},{"issue":"7Supplement","key":"4964_CR54","doi-asserted-by":"publisher","first-page":"CT247","DOI":"10.1158\/1538-7445.AM2024-CT247","volume":"84","author":"W Fang","year":"2024","unstructured":"Fang W, Cheng Y, Chen Z, Wang W, Li Y, Yin Y et al (2024) Abstract CT247: Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in Phase 2 study. Cancer Res 84(7Supplement):CT247\u2013CT","journal-title":"Cancer Res"},{"issue":"6","key":"4964_CR55","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1038\/s41591-025-03638-2","volume":"31","author":"S Zhao","year":"2025","unstructured":"Zhao S, Cheng Y, Wang Q, Li X, Liao J, Rodon J et al (2025) Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1\/2 and phase 2 trials. Nat Med 31(6):1976\u20131986. https:\/\/doi.org\/10.1038\/s41591-025-03638-2","journal-title":"Nat Med"},{"issue":"1","key":"4964_CR56","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa2512071","volume":"394","author":"W Fang","year":"2026","unstructured":"Fang W, Wu L, Meng X, Yao Y, Zuo W, Yao W et al (2026) Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC. N Engl J Med 394(1):13\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2512071","journal-title":"N Engl J Med"},{"key":"4964_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03883-5","author":"S Hong","year":"2025","unstructured":"Hong S, Wang Q, Cheng Y, Luo Y, Qu X, Zhu H et al (2025) First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-03883-5","journal-title":"Nat Med"},{"issue":"1","key":"4964_CR58","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.Cd-21-0715","volume":"12","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, Baik C, Su WC, Johnson ML, Hayashi H, Nishio M et al (2022) Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Discov 12(1):74\u201389. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0715","journal-title":"Cancer Discov"},{"issue":"35","key":"4964_CR59","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1200\/jco.23.01476","volume":"41","author":"HA Yu","year":"2023","unstructured":"Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M et al (2023) HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. J Clin Oncol 41(35):5363\u20135375. https:\/\/doi.org\/10.1200\/jco.23.01476","journal-title":"J Clin Oncol"},{"key":"4964_CR60","doi-asserted-by":"crossref","unstructured":"Mok TS, Yu HA, Lim SM, Okamoto I, Perol M, Novello S et al (2025) Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFR m) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. American Society of Clinical Oncology","DOI":"10.1200\/JCO.2025.43.16_suppl.8506"},{"issue":"7","key":"4964_CR61","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/s1470-2045(24)00159-1","volume":"25","author":"Y Ma","year":"2024","unstructured":"Ma Y, Huang Y, Zhao Y, Zhao S, Xue J, Yang Y et al (2024) BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol 25(7):901\u2013911. https:\/\/doi.org\/10.1016\/s1470-2045(24)00159-1","journal-title":"Lancet Oncol"},{"issue":"6","key":"4964_CR62","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.annonc.2026.01.009","volume":"37","author":"SD Hong","year":"2026","unstructured":"Hong SD, Wang YS, Zhao HY, Zhao YY, Wang QM, Ma YX et al (2026) Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials. Ann Oncol 37(6):813\u2013824. https:\/\/doi.org\/10.1016\/j.annonc.2026.01.009","journal-title":"Ann Oncol"},{"key":"4964_CR63","doi-asserted-by":"publisher","first-page":"S563","DOI":"10.1016\/j.annonc.2025.08.1490","volume":"36","author":"HA Yu","year":"2025","unstructured":"Yu HA, Le X, Johnson ML, Iannotti N, Spira AI, J\u00e4nne PA et al (2025) 921MO Phase I global study of Iza-Bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and other solid tumors. Ann Oncol 36:S563\u2013S4. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.1490","journal-title":"Ann Oncol"},{"issue":"2","key":"4964_CR64","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3779\/j.issn.1009-3419.2025.102.01","volume":"28","author":"J Chen","year":"2025","unstructured":"Chen J, Han B, Hu Y, Hu J (2025) [Expert Consensus on Diagnosis and Treatment of NSCLC with MET Abnormalities (2025 Version)]. Zhongguo Fei Ai Za Zhi 28(2):81\u201394. https:\/\/doi.org\/10.3779\/j.issn.1009-3419.2025.102.01","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"4","key":"4964_CR65","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1158\/1078-0432.Ccr-16-1568","volume":"23","author":"J Wang","year":"2017","unstructured":"Wang J, Anderson MG, Oleksijew A, Vaidya KS, Boghaert ER, Tucker L et al (2017) ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence. Clin Cancer Res 23(4):992\u20131000. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-1568","journal-title":"Clin Cancer Res"},{"issue":"25","key":"4964_CR66","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/jco.24.00720","volume":"42","author":"DR Camidge","year":"2024","unstructured":"Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E et al (2024) Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. J Clin Oncol 42(25):3000\u20133011. https:\/\/doi.org\/10.1200\/jco.24.00720","journal-title":"J Clin Oncol"},{"issue":"24","key":"4964_CR67","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1158\/1078-0432.Ccr-19-4051","volume":"26","author":"S Decary","year":"2020","unstructured":"Decary S, Berne PF, Nicolazzi C, Lefebvre AM, Dabdoubi T, Cameron B et al (2020) Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors. Clin Cancer Res 26(24):6589\u20136599. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-4051","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4964_CR68","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.annonc.2021.12.012","volume":"33","author":"A Gazzah","year":"2022","unstructured":"Gazzah A, Bedard PL, Hierro C, Kang YK, Abdul Razak A, Ryu MH et al (2022) Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol 33(4):416\u2013425. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.012","journal-title":"Ann Oncol"},{"issue":"10","key":"4964_CR69","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jtho.2024.09.050","volume":"19","author":"B Besse","year":"2024","unstructured":"Besse B, Russo GL, Lena H, Nadal E, Cousin S, Kowalski D et al (2024) OA08. 05 tusamitamab ravtansine vs docetaxel in previously treated advanced nonsquamous NSCLC: results from phase 3 CARMEN-LC03 trial. J Thorac Oncol 19(10):S25\u2013S6","journal-title":"J Thorac Oncol"},{"key":"4964_CR70","doi-asserted-by":"crossref","unstructured":"Lentz RW, Ng MC, Yong W-P, Meric-Bernstam F, Singh I, Srirangam V et al (2025) Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study. American Society of Clinical Oncology","DOI":"10.1200\/JCO.2025.43.16_suppl.4018"},{"issue":"10","key":"4964_CR71","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1038\/s41591-025-03843-z","volume":"31","author":"S Kopetz","year":"2025","unstructured":"Kopetz S, Boni V, Kato K, Raghav KPS, Vieito M, Pallis A et al (2025) Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial. Nat Med 31(10):3504\u20133513. https:\/\/doi.org\/10.1038\/s41591-025-03843-z","journal-title":"Nat Med"},{"key":"4964_CR72","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.annonc.2026.05.163","volume":"37","author":"K Raghav","year":"2026","unstructured":"Raghav K, Taieb J, Ma B, Stintzing S, Yamaguchi K, Xu R et al (2026) 164TiP PROCEADE-CRC-03: A phase III study of precemtabart tocentecan (Precem-TcT), as monotherapy or plus bevacizumab, in patients with advanced metastatic colorectal cancer (mCRC). Ann Oncol 37:S65","journal-title":"Ann Oncol"},{"issue":"16","key":"4964_CR73","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1158\/1078-0432.Ccr-20-3757","volume":"27","author":"ML Maitland","year":"2021","unstructured":"Maitland ML, Sachdev JC, Sharma MR, Moreno V, Boni V, Kummar S et al (2021) First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. Clin Cancer Res 27(16):4511\u20134520. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-3757","journal-title":"Clin Cancer Res"},{"key":"4964_CR74","doi-asserted-by":"publisher","first-page":"104755","DOI":"10.1016\/j.yexmp.2022.104755","volume":"125","author":"M Li","year":"2022","unstructured":"Li M, Che N, Feng Y, Liu X, Piao L, Xuan Y et al (2022) B7-H4 expression promotes non-small cell lung cancer progression via AMPK\/mTOR signaling. Exp Mol Pathol 125:104755. https:\/\/doi.org\/10.1016\/j.yexmp.2022.104755","journal-title":"Exp Mol Pathol"},{"issue":"2","key":"4964_CR75","doi-asserted-by":"publisher","first-page":"153","DOI":"10.36401\/jipo-24-34","volume":"8","author":"M Phipps","year":"2025","unstructured":"Phipps M, Falchook GS (2025) B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review. J Immunother Precis Oncol 8(2):153\u2013160. https:\/\/doi.org\/10.36401\/jipo-24-34","journal-title":"J Immunother Precis Oncol"},{"key":"4964_CR76","doi-asserted-by":"publisher","unstructured":"Gray E, Ulrich M, Epp A, Younan P, Sahetya D, Hensley K et al (2023) SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models. J Immunother Cancer 11(10). https:\/\/doi.org\/10.1136\/jitc-2023-007572","DOI":"10.1136\/jitc-2023-007572"},{"key":"4964_CR77","doi-asserted-by":"publisher","first-page":"115603","DOI":"10.1016\/j.ejca.2025.115603","volume":"227","author":"K Muro","year":"2025","unstructured":"Muro K, Feinstein T, Baranda J, Bonta I, Yanagitani N, Gersten T et al (2025) Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1\/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study. Eur J Cancer 227:115603. https:\/\/doi.org\/10.1016\/j.ejca.2025.115603","journal-title":"Eur J Cancer"},{"key":"4964_CR78","doi-asserted-by":"publisher","first-page":"122910","DOI":"10.1016\/j.lfs.2024.122910","volume":"352","author":"MJ Khosravanian","year":"2024","unstructured":"Khosravanian MJ, Mirzaei Y, Mer AH, Keyhani-Khankahdani M, Abdinia FS, Misamogooe F et al (2024) Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence. Life Sci 352:122910. https:\/\/doi.org\/10.1016\/j.lfs.2024.122910","journal-title":"Life Sci"},{"key":"4964_CR79","doi-asserted-by":"publisher","unstructured":"Syal A, Meyer ML, Angelino K, Osei N, Gomez JE, Sen T et al (2025) Antibody drugs conjugates in non-small cell lung cancer: current status and challenges. Oncologist 30(11). https:\/\/doi.org\/10.1093\/oncolo\/oyaf331","DOI":"10.1093\/oncolo\/oyaf331"},{"issue":"10","key":"4964_CR80","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3779\/j.issn.1009-3419.2021.101.36","volume":"24","author":"M Xu","year":"2021","unstructured":"Xu M, Zhang J, Su Y, Li X (2021) [Advances in Molecular Typing of Small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 24(10):734\u2013738. https:\/\/doi.org\/10.3779\/j.issn.1009-3419.2021.101.36","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"21","key":"4964_CR81","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/jama.2025.0560","volume":"333","author":"SY Kim","year":"2025","unstructured":"Kim SY, Park HS, Chiang AC (2025) Small Cell Lung Cancer: A Review. JAMA 333(21):1906\u20131917. https:\/\/doi.org\/10.1001\/jama.2025.0560","journal-title":"JAMA"},{"issue":"7","key":"4964_CR82","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","volume":"32","author":"AC Dingemans","year":"2021","unstructured":"Dingemans AC, Fr\u00fch M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE et al (2021) Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606). Ann Oncol 32(7):839\u2013853. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.207","journal-title":"Ann Oncol"},{"issue":"11","key":"4964_CR83","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/oncolo\/oyac161","volume":"27","author":"J Yao","year":"2022","unstructured":"Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS et al (2022) DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist 27(11):940\u2013951. https:\/\/doi.org\/10.1093\/oncolo\/oyac161","journal-title":"Oncologist"},{"issue":"1","key":"4964_CR84","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12672-024-01171-1","volume":"15","author":"Y Meng","year":"2024","unstructured":"Meng Y, Wang X, Yang J, Zhu M, Yu M, Li L et al (2024) Antibody-drug conjugates treatment of small cell lung cancer: advances in clinical research. Discov Oncol 15(1):327. https:\/\/doi.org\/10.1007\/s12672-024-01171-1","journal-title":"Discov Oncol"},{"issue":"1","key":"4964_CR85","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12943-024-02012-z","volume":"23","author":"P-L Su","year":"2024","unstructured":"Su P-L, Chakravarthy K, Furuya N, Brownstein J, Yu J, Long M et al (2024) DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy. Mol Cancer 23(1):97","journal-title":"Mol Cancer"},{"key":"4964_CR86","doi-asserted-by":"crossref","unstructured":"Patel MR, Wu Y-LLC, Wang Z, Rocha P, Wang Q, Du Y et al (2025) ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update. American Society of Clinical Oncology","DOI":"10.1200\/JCO.2025.43.16_suppl.3041"},{"issue":"10","key":"4964_CR87","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.jtho.2025.09.046","volume":"20","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Meng X, Zhang Y, Sun L, Wang Q, Fang J et al (2025) OA06. 01 A First-In-Human Phase 1 Study of SHR-4849 (IDE849), a DLL3-Directed Antibody-Drug Conjugate, in Relapsed SCLC. J Thorac Oncol 20(10):S21","journal-title":"J Thorac Oncol"},{"key":"4964_CR88","doi-asserted-by":"crossref","unstructured":"Li W, Sun Y, Dang Q, He Z, Lu M, Ji Y et al (2026) Phase I study of BL-M14D1, a novel DLL3-directed antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small-cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), and other solid tumors. American Society of Clinical Oncology","DOI":"10.1200\/JCO.2026.44.16_suppl.3001"},{"issue":"12","key":"4964_CR89","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","volume":"15","author":"MK Baine","year":"2020","unstructured":"Baine MK, Hsieh MS, Lai WV, Egger JV, Jungbluth AA, Daneshbod Y et al (2020) SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. J Thorac Oncol 15(12):1823\u20131835. https:\/\/doi.org\/10.1016\/j.jtho.2020.09.009","journal-title":"J Thorac Oncol"},{"issue":"6","key":"4964_CR90","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00418-020-01863-z","volume":"153","author":"S Kudoh","year":"2020","unstructured":"Kudoh S, Tenjin Y, Kameyama H, Ichimura T, Yamada T, Matsuo A et al (2020) Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells. Histochem Cell Biol 153(6):443\u2013456. https:\/\/doi.org\/10.1007\/s00418-020-01863-z","journal-title":"Histochem Cell Biol"},{"issue":"1","key":"4964_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-024-00784-7","volume":"9","author":"A Ajay","year":"2025","unstructured":"Ajay A, Wang H, Rezvani A, Savari O, Grubb BJ, McColl KS et al (2025) Assessment of targets of antibody drug conjugates in SCLC. NPJ Precis Oncol 9(1):1. https:\/\/doi.org\/10.1038\/s41698-024-00784-7","journal-title":"NPJ Precis Oncol"},{"issue":"6","key":"4964_CR92","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1158\/1535-7163.Mct-21-0851","volume":"21","author":"WR Wiedemeyer","year":"2022","unstructured":"Wiedemeyer WR, Gavrilyuk J, Schammel A, Zhao X, Sarvaiya H, Pysz M et al (2022) ABBV-011, A Novel, Calicheamicin-Based Antibody-Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors. Mol Cancer Ther 21(6):986\u2013998. https:\/\/doi.org\/10.1158\/1535-7163.Mct-21-0851","journal-title":"Mol Cancer Ther"},{"key":"4964_CR93","doi-asserted-by":"crossref","unstructured":"Byers LA, Cho BC, Cooper AJ, Chiang AC, Han J-Y, Furqan M et al (2026) SEZ6-targeting antibody\u2013 drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial. Nat Med. :1\u201311","DOI":"10.1038\/s41591-026-04452-0"},{"issue":"1","key":"4964_CR94","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","volume":"22","author":"AA Getu","year":"2023","unstructured":"Getu AA, Tigabu A, Zhou M, Lu J, Fodstad \u00d8, Tan M (2023) New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Mol Cancer 22(1):43. https:\/\/doi.org\/10.1186\/s12943-023-01751-9","journal-title":"Mol Cancer"},{"issue":"4","key":"4964_CR95","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1158\/1535-7163.Mct-21-0554","volume":"21","author":"M Yamato","year":"2022","unstructured":"Yamato M, Hasegawa J, Maejima T, Hattori C, Kumagai K, Watanabe A et al (2022) DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models. Mol Cancer Ther 21(4):635\u2013646. https:\/\/doi.org\/10.1158\/1535-7163.Mct-21-0554","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"4964_CR96","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jtho.2024.09.033","volume":"19","author":"CM Rudin","year":"2024","unstructured":"Rudin CM, Ahn M-J, Johnson M, Hann CL, Girard N, Nishio M et al (2024) OA04. 03 ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer (ES-SCLC): interim analysis of ideate-lung01. J Thorac Oncol 19(10):S15\u2013S6","journal-title":"J Thorac Oncol"},{"issue":"10","key":"4964_CR97","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.jtho.2024.09.036","volume":"19","author":"J Wang","year":"2024","unstructured":"Wang J, Duan J, Wu L, Wang Q, Xing L, Sun Y et al (2024) OA04. 06 efficacy and safety of HS-20093 in extensive stage small cell lung cancer in a multicenter, phase 1 study (ARTEMIS-001). J Thorac Oncol 19(10):S17","journal-title":"J Thorac Oncol"},{"issue":"6","key":"4964_CR98","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","volume":"31","author":"Y Ma","year":"2025","unstructured":"Ma Y, Yang Y, Huang Y, Fang W, Xue J, Meng X et al (2025) A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial. Nat Med 31(6):1949\u20131957. https:\/\/doi.org\/10.1038\/s41591-025-03600-2","journal-title":"Nat Med"},{"issue":"1","key":"4964_CR99","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41698-025-01011-7","volume":"9","author":"S Marchesi","year":"2025","unstructured":"Marchesi S, Marinello A, Ambrosini P, Cavalli C, Lo Russo G, Occhipinti M (2025) Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment. NPJ Precis Oncol 9(1):219. https:\/\/doi.org\/10.1038\/s41698-025-01011-7","journal-title":"NPJ Precis Oncol"},{"key":"4964_CR100","doi-asserted-by":"crossref","unstructured":"Shen L, Zhou C, Yu Y, Yu X, Meng X, Sun Y et al (2025) Efficacy and safety of MHB088C, a novel B7-H3-targeted ADC, in patients with relapsed extensive-stage small cell lung cancer (ES-SCLC): Subgroup analysis from a phase 1\/2 multicenter study. American Society of Clinical Oncology","DOI":"10.1200\/JCO.2025.43.16_suppl.8510"},{"key":"4964_CR101","doi-asserted-by":"crossref","unstructured":"Zhang L, Wu L, Zhao H, Zuo J, Ma Y, Zheng T et al (2026) First-in-human study of SYS6043, a novel B7-H3\u2013targeting antibody-drug conjugate, in patients with advanced pan-tumor malignancies. American Society of Clinical Oncology","DOI":"10.1200\/JCO.2026.44.16_suppl.3002"},{"key":"4964_CR102","doi-asserted-by":"publisher","unstructured":"Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R et al (2023) Mechanisms of Resistance to Antibody-Drug Conjugates. Int J Mol Sci 24(11). https:\/\/doi.org\/10.3390\/ijms24119674","DOI":"10.3390\/ijms24119674"},{"key":"4964_CR103","doi-asserted-by":"publisher","unstructured":"Inase A, Kimbara S, Imamura E, Phelps MA, Minami H (2026) Overcoming resistance to antibody-drug conjugates: mechanisms and emerging strategies. Oncologist 31(4). https:\/\/doi.org\/10.1093\/oncolo\/oyag020","DOI":"10.1093\/oncolo\/oyag020"},{"key":"4964_CR104","doi-asserted-by":"publisher","unstructured":"Xie D, Yang C, Gao S, Li J, Yang J, Li X et al (2026) Antibody-Drug Conjugates Targeting Resistance-Associated Signaling Pathways: Recent Advances and Future Perspectives. Int J Mol Sci 27(7). https:\/\/doi.org\/10.3390\/ijms27073287","DOI":"10.3390\/ijms27073287"},{"key":"4964_CR105","doi-asserted-by":"publisher","first-page":"e2400898","DOI":"10.1200\/PO-24-00898","volume":"9","author":"N Mai","year":"2025","unstructured":"Mai N, Klar Lieberman MM, Ferraro E, Bromberg M, Chen Y, Razavi P et al (2025) Sequential antibody-drug conjugate therapy in patients with metastatic breast cancer treated with sacituzumab govitecan and trastuzumab deruxtecan. JCO Precision Oncol 9:e2400898","journal-title":"JCO Precision Oncol"},{"issue":"8","key":"4964_CR106","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1158\/1078-0432.Ccr-25-3321","volume":"32","author":"DR Rampa","year":"2026","unstructured":"Rampa DR, Seo M, Ogata N, Yang Z, Sridhar N, Fujii T et al (2026) Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer. Clin Cancer Res 32(8):1454\u20131461. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-25-3321","journal-title":"Clin Cancer Res"},{"key":"4964_CR107","doi-asserted-by":"crossref","unstructured":"Wen M, Yu A, Park Y, Calarese D, Gerber H-P, Yin G (eds) (2025) Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations. Taylor & Francis, MAbs","DOI":"10.1080\/19420862.2025.2498162"},{"key":"4964_CR108","doi-asserted-by":"publisher","first-page":"116995","DOI":"10.1016\/j.ejmech.2024.116995","volume":"281","author":"J Tao","year":"2025","unstructured":"Tao J, Gu Y, Zhou W, Wang Y (2025) Dual-payload antibody\u2013drug conjugates: Taking a dual shot. Eur J Med Chem 281:116995","journal-title":"Eur J Med Chem"},{"issue":"4","key":"4964_CR109","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1158\/1535-7163.MCT-25-0271","volume":"25","author":"P Ren","year":"2026","unstructured":"Ren P, Guan M, Tang J, Yin S, Qi L, Yue J et al (2026) A novel dual-payload ADC platform integrating exatecan and triptolide to enhance antitumor efficacy and overcome resistance. Mol Cancer Ther 25(4):529\u2013540","journal-title":"Mol Cancer Ther"},{"key":"4964_CR110","doi-asserted-by":"crossref","unstructured":"Chen S, Xiong Y, Cai C, Yu N, Zhang X, Guo Q et al (2026) Preclinical data of IBI3028, the first clinical-stage bispecific dual-payload ADC, targeting EGFR\/c-MET\u2013positive advanced solid tumors. American Society of Clinical Oncology","DOI":"10.1200\/JCO.2026.44.16_suppl.e15020"},{"issue":"7Supplement","key":"4964_CR111","doi-asserted-by":"publisher","first-page":"5736","DOI":"10.1158\/1538-7445.AM2023-5736","volume":"83","author":"F Comer","year":"2023","unstructured":"Comer F, Mazor Y, Hurt E, Yang C, Fleming R, Shandilya H et al (2023) AZD9592: An EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond. Cancer Res 83(7Supplement):5736","journal-title":"Cancer Res"},{"key":"4964_CR112","doi-asserted-by":"publisher","first-page":"S749","DOI":"10.1016\/j.annonc.2022.07.589","volume":"33","author":"K Jhaveri","year":"2022","unstructured":"Jhaveri K, Han H, Dotan E, Oh D, Ferrario C, Tolcher A et al (2022) 460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers. Ann Oncol 33:S749\u2013S50","journal-title":"Ann Oncol"},{"issue":"5","key":"4964_CR113","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","volume":"14","author":"Y Gu","year":"2024","unstructured":"Gu Y, Wang Z, Wang Y (2024) Bispecific antibody drug conjugates: Making 1\u2009+\u20091> 2. Acta Pharm Sinica B 14(5):1965\u20131986","journal-title":"Acta Pharm Sinica B"},{"issue":"9","key":"4964_CR114","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1158\/1535-7163.MCT-19-1004","volume":"19","author":"L Skidmore","year":"2020","unstructured":"Skidmore L, Sakamuri S, Knudsen NA, Hewet AG, Milutinovic S, Barkho W et al (2020) ARX788, a site-specific anti-HER2 antibody\u2013drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1\u2013resistant breast and gastric cancers. Mol Cancer Ther 19(9):1833\u20131843","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"4964_CR115","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-025-01720-3","volume":"18","author":"HN Tan","year":"2025","unstructured":"Tan HN, Morcillo MA, Lopez J, Minchom A, Sharp A, Paschalis A et al (2025) Treatment-related adverse events of antibody drug-conjugates in clinical trials. J Hematol Oncol 18(1):71. https:\/\/doi.org\/10.1186\/s13045-025-01720-3","journal-title":"J Hematol Oncol"},{"issue":"22","key":"4964_CR116","doi-asserted-by":"publisher","first-page":"e70178","DOI":"10.1111\/1759-7714.70178","volume":"16","author":"Y Li","year":"2025","unstructured":"Li Y, Zhou L, Li S, Zhou S, Chen Y, Tong Y et al (2025) Treatment-Related Adverse Events of Antibody-Drug Conjugate Monotherapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Thorac Cancer 16(22):e70178. https:\/\/doi.org\/10.1111\/1759-7714.70178","journal-title":"Thorac Cancer"},{"issue":"3","key":"4964_CR117","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/jco-24-01544","volume":"43","author":"MJ Ahn","year":"2025","unstructured":"Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E et al (2025) Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol 43(3):260\u2013272. https:\/\/doi.org\/10.1200\/jco-24-01544","journal-title":"J Clin Oncol"},{"key":"4964_CR118","doi-asserted-by":"publisher","first-page":"102378","DOI":"10.1016\/j.ctrv.2022.102378","volume":"106","author":"SM Swain","year":"2022","unstructured":"Swain SM, Nishino M, Lancaster LH, Li BT, Nicholson AG, Bartholmai BJ et al (2022) Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev 106:102378. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102378","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"4964_CR119","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s43046-025-00264-4","volume":"37","author":"S Soni","year":"2025","unstructured":"Soni S, Megha K, Shah VB, Shah AC, Bhatt S, Merja M et al (2025) Unlocking the therapeutic potential of antibody-drug conjugates in targeting molecular biomarkers in non-small cell lung cancer. J Egypt Natl Canc Inst 37(1):6. https:\/\/doi.org\/10.1186\/s43046-025-00264-4","journal-title":"J Egypt Natl Canc Inst"},{"key":"4964_CR120","doi-asserted-by":"publisher","first-page":"102395","DOI":"10.1016\/j.ctrv.2022.102395","volume":"106","author":"E Nicol\u00f2","year":"2022","unstructured":"Nicol\u00f2 E, Giugliano F, Ascione L, Tarantino P, Corti C, Tolaney SM et al (2022) Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat Rev 106:102395. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102395","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"4964_CR121","doi-asserted-by":"publisher","first-page":"103509","DOI":"10.1016\/j.jtho.2025.10.016","volume":"21","author":"M Reck","year":"2026","unstructured":"Reck M, Patel JD, Gray JE, Reguart N, Cobo M, Pradera JF et al (2026) First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study. J Thorac Oncol 21(3):103509. https:\/\/doi.org\/10.1016\/j.jtho.2025.10.016","journal-title":"J Thorac Oncol"},{"key":"4964_CR122","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-25-4485","author":"JE Gray","year":"2026","unstructured":"Gray JE, Neal JW, Patel JD, Liu SV, Veillon R, Reck M et al (2026) First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-25-4485","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4964_CR123","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.annonc.2026.02.014","volume":"37","author":"JW Riess","year":"2026","unstructured":"Riess JW, Yu HA, Le X, de Langen AJ, Cho BC, Piotrowska Z et al (2026) Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD. Ann Oncol 37(6):825\u2013836. https:\/\/doi.org\/10.1016\/j.annonc.2026.02.014","journal-title":"Ann Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04964-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04964-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04964-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:02:04Z","timestamp":1791928924000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04964-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":123,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4964"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04964-z","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"18 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since this article is a narrative review and the article does not entail direct work with human participants, animal subjects and clinical samples, ethical approval was unnecessary.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"118"}}